BRAF and cancer: The Rare Oncology Agnostic Research (ROAR) basket trial (NCT02034110), was designed to determine as primary study endpoint the ORR of dabrafenib in combination with trametinib in patients with rare BRAF V600E-mutated cancers, including 43 patients with advanced BRAF V600E mutated BTC (iCCA patients, n = 39).